182 related articles for article (PubMed ID: 17050493)
1. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system.
Yee RW; Norcom EG; Zhao XC
Adv Ther; 2006; 23(4):511-9. PubMed ID: 17050493
[TBL] [Abstract][Full Text] [Related]
2. In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells.
Kahook MY; Ammar DA
J Ocul Pharmacol Ther; 2010 Jun; 26(3):259-63. PubMed ID: 20565312
[TBL] [Abstract][Full Text] [Related]
3. Reduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium-preserved travoprost or latanoprost ophthalmic solutions.
Liang H; Brignole-Baudouin F; Riancho L; Baudouin C
Ophthalmic Res; 2012; 48(2):89-101. PubMed ID: 22473057
[TBL] [Abstract][Full Text] [Related]
4. Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and/or antihypertensive agents.
Whitson JT; Petroll WM
Adv Ther; 2012 Oct; 29(10):874-88. PubMed ID: 23065664
[TBL] [Abstract][Full Text] [Related]
5. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost.
Baudouin C; Riancho L; Warnet JM; Brignole F
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4123-8. PubMed ID: 17724196
[TBL] [Abstract][Full Text] [Related]
6. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.
Ammar DA; Noecker RJ; Kahook MY
Adv Ther; 2010 Nov; 27(11):837-45. PubMed ID: 20931366
[TBL] [Abstract][Full Text] [Related]
7. In vitro comparative toxicology of polyquad-preserved and benzalkonium chloride-preserved travoprost/timolol fixed combination and latanoprost/timolol fixed combination.
Brignole-Baudouin F; Riancho L; Liang H; Nakib Z; Baudouin C
J Ocul Pharmacol Ther; 2011 Jun; 27(3):273-80. PubMed ID: 21410334
[TBL] [Abstract][Full Text] [Related]
8. Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and non-pigmented ciliary epithelial cell lines.
Ammar DA; Kahook MY
Br J Ophthalmol; 2011 Oct; 95(10):1466-9. PubMed ID: 21602479
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells.
Brignole-Baudouin F; Riancho L; Liang H; Baudouin C
Curr Eye Res; 2011 Nov; 36(11):979-88. PubMed ID: 21999224
[TBL] [Abstract][Full Text] [Related]
10. Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells.
Ammar DA; Kahook MY
Mol Vis; 2011; 17():1806-13. PubMed ID: 21750606
[TBL] [Abstract][Full Text] [Related]
11. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears.
Kahook MY; Noecker RJ
Cornea; 2008 Apr; 27(3):339-43. PubMed ID: 18362664
[TBL] [Abstract][Full Text] [Related]
12. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride.
Whitson JT; Cavanagh HD; Lakshman N; Petroll WM
Adv Ther; 2006; 23(5):663-71. PubMed ID: 17142200
[TBL] [Abstract][Full Text] [Related]
13. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells.
Guenoun JM; Baudouin C; Rat P; Pauly A; Warnet JM; Brignole-Baudouin F
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2444-50. PubMed ID: 15980234
[TBL] [Abstract][Full Text] [Related]
14. In vivo corneal epithelial permeability following treatment with prostaglandin analogs [correction of analoges] with or without benzalkonium chloride.
McCarey B; Edelhauser H
J Ocul Pharmacol Ther; 2007 Oct; 23(5):445-51. PubMed ID: 17941807
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system.
Ryan G; Fain JM; Lovelace C; Gelotte KM
BMC Ophthalmol; 2011 Apr; 11():8. PubMed ID: 21510881
[TBL] [Abstract][Full Text] [Related]
16. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
[TBL] [Abstract][Full Text] [Related]
17. A novel ophthalmic latanoprost 0.005% nanoemulsion: a cytotoxicity study.
Tau J; Passerini MS; Del Papa M; Aguilar A; Berra A
Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1941-1946. PubMed ID: 35015115
[TBL] [Abstract][Full Text] [Related]
18. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
19. Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets.
Nakagawa S; Usui T; Yokoo S; Omichi S; Kimakura M; Mori Y; Miyata K; Aihara M; Amano S; Araie M
Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5154-60. PubMed ID: 22695966
[TBL] [Abstract][Full Text] [Related]
20. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells.
Guenoun JM; Baudouin C; Rat P; Pauly A; Warnet JM; Brignole-Baudouin F
Invest Ophthalmol Vis Sci; 2005 Dec; 46(12):4594-9. PubMed ID: 16303954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
